Short Interest in Autonomix Medical, Inc. (NASDAQ:AMIX) Decreases By 29.7%

Autonomix Medical, Inc. (NASDAQ:AMIX) was the target of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 99,700 shares, a decline of 29.7% from the January 31st total of 141,900 shares. Approximately 8.0% of the company’s stock are short sold. Based on an average daily volume of 377,400 shares, the days-to-cover ratio is currently 0.3 days.

Autonomix Medical Trading Down 13.5 %

Shares of AMIX stock opened at $2.38 on Tuesday. Autonomix Medical has a 12-month low of $2.38 and a 12-month high of $82.00. The business’s fifty day simple moving average is $2.99 and its 200-day simple moving average is $7.86. The company has a market cap of $5.86 million and a PE ratio of -0.18.

Autonomix Medical (NASDAQ:AMIX) last announced its earnings results on Thursday, February 13th. The company reported ($1.46) earnings per share for the quarter. On average, equities analysts forecast that Autonomix Medical will post -10 earnings per share for the current year.

Hedge Funds Weigh In On Autonomix Medical

An institutional investor recently bought a new position in Autonomix Medical stock. Citadel Advisors LLC bought a new position in shares of Autonomix Medical, Inc. (NASDAQ:AMIX) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 47,884 shares of the company’s stock, valued at approximately $180,000. Citadel Advisors LLC owned about 4.16% of Autonomix Medical at the end of the most recent quarter. Institutional investors and hedge funds own 10.78% of the company’s stock.

About Autonomix Medical

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals.